Increase in Authorized SHare Capital from 14cr to 20cr.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Eiko Lifesciences Ltd, at a meeting held on 29th July 2025, approved an increase in the company's authorized share capital from ₹14 crore (1.4 crore equity shares of ₹10 each) to ₹20 crore (2 crore equity shares of ₹10 each). This represents an increase of ₹6 crore, or about 43% in authorized capital headroom. The Memorandum of Association will be amended accordingly to reflect the new Clause V, subject to shareholder approval. No changes are proposed to the Articles of Association. This step is typically taken to create room for future corporate actions such as a stock split, bonus issue, or fundraising, though the filing itself does not specify the intended use.
For shareholders, this is a procedural step that creates capacity for future equity actions — it does not change existing shareholdings or earnings. The actual impact on the stock will depend on what the company plans to do with this newly created authorized capital, which has not been disclosed yet.